Quantoom Biosciences and TriLink BioTechnologies Sign a Supply and License Agreement

TriLink BioTechnologies®, a division of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), announced a non-exclusive License and Supply Agreement with Quantoom Biosciences on June 3, 2025.

Quantoom Biosciences and TriLink BioTechnologies sign a supply and license agreement

A researcher in a laboratory coat working with laboratory equipment for nucleic acids.

Through this agreement, Quantoom will be able to integrate TriLink’s CleanCap® mRNA capping technology into its Ntensify® platform, facilitating effective RNA synthesis and wider distribution of vaccines and treatments, especially in areas with limited resources.

The majority of authorized COVID-19 mRNA and saRNA vaccines use TriLink’s CleanCap®, which was first developed in 2017 and has a capping efficiency of above 95%. Its co-transcriptional capping mechanism speeds up production and greatly increases mRNA yield.

The 2023 debut of Quantoom’s Ntensify® platform, which combines design, production, and formulation capabilities into a scalable RNA manufacturing system, has gained widespread acceptance due to its effectiveness.

The deal allows researchers to progress (sa)mRNA medication development through clinical stages by adding CleanCap analogs to Quantoom’s platform. Executives from both businesses stressed how the collaboration will help increase access to vital RNA-based medications around the world.

While we acknowledge the potential of MRVI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRVI and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.